Congress clarifies opioid grants can fund public naloxone kits
H.R. 5252 — HOPE Act · Filed by Gabe Amo (D-RI) · 7 cosponsors · Introduced Sep 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the 21st Century Cures Act to allow states and tribes to use existing federal opioid-response grants to purchase, distribute, and maintain public access overdose reversal kits (naloxone/Narcan). It adds a definition of what counts as a 'public access opioid overdose reversal kit' to clarify eligible uses of grant funds already appropriated for opioid disorder response.
Why we flagged it
The bill is a narrow, technical amendment to existing opioid-response law that clarifies eligible uses of federal grants. It is not a new appropriation, new agency, or new program—it is a definitional clarification enabling states and tribes to deploy overdose-reversal kits using money already designated for opioid response.
What the text implies
- The bill does not appropriate new money; it clarifies use of existing grants. Implementation depends on whether states and tribes choose to reallocate existing opioid-response budgets toward kits rather than other interventions (treatment, prevention, recovery services). No guarantee of increased kit distribution if states prioritize other uses.
- Public access kits require ongoing maintenance and replacement; the bill permits grant funds to cover this, but does not specify funding levels or timelines, leaving sustainability dependent on state/tribal budget decisions.
The full analysis lists 3 implications of this text.
Who stands to gain
naloxone/Narcan manufacturers (increased demand for kits); state and tribal health departments (expanded grant flexibility)